Global Nanotechnology in Drug Delivery Industry

Global Nanotechnology in Drug Delivery Industry

  • April 2021 •
  • 145 pages •
  • Report ID: 5621749 •
  • Format: PDF
Abstract:
- Global Nanotechnology in Drug Delivery Market to Reach $164.1 Billion by 2027
- Amid the COVID-19 crisis, the global market for Nanotechnology in Drug Delivery estimated at US$47.5 Billion in the year 2020, is projected to reach a revised size of US$164.1 Billion by 2027, growing at aCAGR of 19.4% over the period 2020-2027. Nanocrystals, one of the segments analyzed in the report, is projected to record 17.3% CAGR and reach US$83.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Nanocarriers segment is readjusted to a revised 21.9% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $12.8 Billion, While China is Forecast to Grow at 24.5% CAGR
- The Nanotechnology in Drug Delivery market in the U.S. is estimated at US$12.8 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$38.8 Billion by the year 2027 trailing a CAGR of 24.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 14.2% and 17% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 15.2% CAGR.

- Select Competitors (Total 43 Featured) -
  • AbbVie Inc.
  • Aquanova AG
  • BlueWillow Biologics
  • Camurus AB
  • Celgene, Inc.
  • Ceramisphere Health Pty Limited
  • Cristal Therapeutics
  • CYTIMMUNE SCIENCES, Inc.
  • EnColl Corporation
  • EyePoint Pharmaceuticals
  • Lena Nanoceutics Ltd.
  • Nanobiotix
  • NanoCarrier Co., Ltd.
  • NanOlogy LLC
  • Nanospectra Biosciences, Inc.
  • Parvus Therapeutics Inc.
  • Selecta Biosciences
  • Starpharma Holdings Limited
  • Taiwan Liposome Co.,
  • Tarveda Therapeutics